Omrix Biopharmaceuticals Inc.

Itai Podoler

Israel Nur

Lior Weissman

Tamara Byk-Tennenbaum

Erez Ilan

Ronen Eavri

Elena Grimberg

Inbar Gahali-Sass

The invention relates to a viral inactivated biological liquid or dry mixture and to its preparation. Principally, the invention relates, but is not limited, to a mixture derived from a platelet source.

Viral inactivated biological mixture

Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.

Low concentrated protein compositions for preventing tissue adhesion

Growing community of inventors

Rehovot, Israel

Itai Podoler